BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» PDL Enters Eos Buyout Deal To Gain Platform, Early Drugs
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
PDL Enters Eos Buyout Deal To Gain Platform, Early Drugs
Feb. 6, 2003
By
Randy Osborne
No Comments
A year after shareholders of a different firm put the kibosh on a planned merger with privately held Eos Biotechnology Inc., Protein Design Labs Inc. said it has entered an agreement to pay $37.5 million for the spurned company. (BioWorld Today)
BioWorld